Prognostic and Predictive Biomarkers in Prostate Cancer: Latest Evidence and Clinical Implications

Overview

Journal Ther Adv Med Oncol

Specialty Oncology

Date 2017 Aug 11

PMID 28794807

Citations 35

Authors

Naoki Terada

Shusuke Akamatsu

Takashi Kobayashi

Takahiro Inoue

Osamu Ogawa

Emmanuel S Antonarakis

Affiliations

Soon will be listed here.

Abstract

Advances in our understanding of the mechanisms driving castration-resistant prostate cancer have promoted the development of several new drugs including androgen receptor-directed therapy and chemotherapy. Concomitant docetaxel treatment at the beginning of hormonal therapy for metastatic prostate cancer has resulted in longer overall survival than with hormonal therapy alone. Elucidating an appropriate treatment sequence using these therapies is important for maximizing clinical benefit in castration-sensitive and castration-resistant prostate cancer patients. The development of advanced high-throughput 'omics' technology has enabled the use of novel markers to guide prognosis and treatment of this disease. In this review, we outline the genomic landscape of prostate cancer and the molecular mechanisms of castration-resistant progression, and how these affect the development of new drugs, and their clinical implications for selecting treatment sequence. We also discuss many of the potential tissue-based or liquid biomarkers that may soon enter clinical use, with the hope that several of these prognostic or predictive markers will guide precision medicine for prostate cancer patients in the near future.

Citing Articles

Clinico-Pathological Factors and AR-LBD Mutations in Early and Late Castration-Resistant Prostate Cancer.

Deswal M, Yadav D, Kumar V, Meenu M, Tanwar P, Srivastava S Cancer Manag Res. 2024; 16:1509-1516.

PMID: 39464307 PMC: 11505485. DOI: 10.2147/CMAR.S477439.

Tumor biomarkers for diagnosis, prognosis and targeted therapy.

Zhou Y, Tao L, Qiu J, Xu J, Yang X, Zhang Y Signal Transduct Target Ther. 2024; 9(1):132.

PMID: 38763973 PMC: 11102923. DOI: 10.1038/s41392-024-01823-2.

High expression of Trop2 is associated with aggressive localized prostate cancer and is a candidate urinary biomarker.

Liu S, Hawley S, Kunder C, Hsu E, Shen M, Westphalen L Sci Rep. 2024; 14(1):486.

PMID: 38177207 PMC: 10766957. DOI: 10.1038/s41598-023-50215-z.

From molecular mechanisms of prostate cancer to translational applications: based on multi-omics fusion analysis and intelligent medicine.

Ren S, Li J, Dorado J, Sierra A, Gonzalez-Diaz H, Duardo A Health Inf Sci Syst. 2023; 12(1):6.

PMID: 38125666 PMC: 10728428. DOI: 10.1007/s13755-023-00264-5.

Molecular pathogenesis, mechanism and therapy of Cav1 in prostate cancer.

Bian Q, Li B, Zhang L, Sun Y, Zhao Z, Ding Y Discov Oncol. 2023; 14(1):196.

PMID: 37910338 PMC: 10620365. DOI: 10.1007/s12672-023-00813-0.

References

Chen C, Welsbie D, Tran C, Baek S, Chen R, Vessella R . Molecular determinants of resistance to antiandrogen therapy. Nat Med. 2004; 10(1):33-9. DOI: 10.1038/nm972. View

Antonarakis E, Luo J . Blood Based Detection of Androgen Receptor Splice Variants in Patients with Advanced Prostate Cancer. J Urol. 2016; 196(6):1606-1607. DOI: 10.1016/j.juro.2016.09.001. View

Liang D, Ensor J, Liu Z, Patel A, Patel T, Chang J . Cell-free DNA as a molecular tool for monitoring disease progression and response to therapy in breast cancer patients. Breast Cancer Res Treat. 2015; 155(1):139-49. DOI: 10.1007/s10549-015-3635-5. View

Antonarakis E, Lu C, Luber B, Wang H, Chen Y, Zhu Y . Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men With Metastatic Castration-Resistant Prostate Cancer Treated With First- and Second-Line Abiraterone and Enzalutamide. J Clin Oncol. 2017; 35(19):2149-2156. PMC: 5493048. DOI: 10.1200/JCO.2016.70.1961. View

Pritchard C, Mateo J, Walsh M, De Sarkar N, Abida W, Beltran H . Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. N Engl J Med. 2016; 375(5):443-53. PMC: 4986616. DOI: 10.1056/NEJMoa1603144. View

Halabi S, Lin C, Kelly W, Fizazi K, Moul J, Kaplan E . Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer. J Clin Oncol. 2014; 32(7):671-7. PMC: 3927736. DOI: 10.1200/JCO.2013.52.3696. View

Saal L, Johansson P, Holm K, Gruvberger-Saal S, She Q, Maurer M . Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. Proc Natl Acad Sci U S A. 2007; 104(18):7564-9. PMC: 1855070. DOI: 10.1073/pnas.0702507104. View

Korpal M, Korn J, Gao X, Rakiec D, Ruddy D, Doshi S . An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide). Cancer Discov. 2013; 3(9):1030-43. DOI: 10.1158/2159-8290.CD-13-0142. View

Mateo J, Boysen G, Barbieri C, Bryant H, Castro E, Nelson P . DNA Repair in Prostate Cancer: Biology and Clinical Implications. Eur Urol. 2016; 71(3):417-425. DOI: 10.1016/j.eururo.2016.08.037. View

10.

Tannock I, de Wit R, Berry W, Horti J, Pluzanska A, Chi K . Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004; 351(15):1502-12. DOI: 10.1056/NEJMoa040720. View

11.

Schwarzenbach H, Hoon D, Pantel K . Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer. 2011; 11(6):426-37. DOI: 10.1038/nrc3066. View

12.

Yoshimoto M, Joshua A, Cunha I, Coudry R, Fonseca F, Ludkovski O . Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome. Mod Pathol. 2008; 21(12):1451-60. DOI: 10.1038/modpathol.2008.96. View

13.

Mehta S, Shelling A, Muthukaruppan A, Lasham A, Blenkiron C, Laking G . Predictive and prognostic molecular markers for cancer medicine. Ther Adv Med Oncol. 2011; 2(2):125-48. PMC: 3126011. DOI: 10.1177/1758834009360519. View

14.

Jeronimo C, Bastian P, Bjartell A, Carbone G, Catto J, Clark S . Epigenetics in prostate cancer: biologic and clinical relevance. Eur Urol. 2011; 60(4):753-66. DOI: 10.1016/j.eururo.2011.06.035. View

15.

Thompson I, Pauler D, Goodman P, Tangen C, Lucia M, Parnes H . Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med. 2004; 350(22):2239-46. DOI: 10.1056/NEJMoa031918. View

16.

Kobayashi T, Inoue T, Kamba T, Ogawa O . Experimental evidence of persistent androgen-receptor-dependency in castration-resistant prostate cancer. Int J Mol Sci. 2013; 14(8):15615-35. PMC: 3759876. DOI: 10.3390/ijms140815615. View

17.

Kawahara T, Yokomizo Y, Ito Y, Ito H, Ishiguro H, Teranishi J . Pretreatment neutrophil-to-lymphocyte ratio predicts the prognosis in patients with metastatic prostate cancer. BMC Cancer. 2016; 16:111. PMC: 4754823. DOI: 10.1186/s12885-016-2134-3. View

18.

Goto T, Terada N, Inoue T, Nakayama K, Okada Y, Yoshikawa T . The expression profile of phosphatidylinositol in high spatial resolution imaging mass spectrometry as a potential biomarker for prostate cancer. PLoS One. 2014; 9(2):e90242. PMC: 3938652. DOI: 10.1371/journal.pone.0090242. View

19.

Leinonen K, Tolonen T, Bracken H, Stenman U, Tammela T, Saramaki O . Association of SPINK1 expression and TMPRSS2:ERG fusion with prognosis in endocrine-treated prostate cancer. Clin Cancer Res. 2010; 16(10):2845-51. DOI: 10.1158/1078-0432.CCR-09-2505. View

20.

Reid A, Attard G, Ambroisine L, Fisher G, Kovacs G, Brewer D . Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer. Br J Cancer. 2010; 102(4):678-84. PMC: 2837564. DOI: 10.1038/sj.bjc.6605554. View